Literature DB >> 23316916

The use of psychotropic drugs in irritable bowel syndrome.

Roy Dekel1, Douglas A Drossman, Ami D Sperber.   

Abstract

INTRODUCTION: Irritable bowel syndrome (IBS), the most common functional gastrointestinal disorder, is manifested by chronic abdominal pain associated with irregular bowel movements. Although not life threatening, IBS is associated with impaired quality of life that ranges from mild to severe. AREAS COVERED: The pathogenesis of IBS is not completely understood, but involves dysfunction of the "brain-gut axis" including peripheral visceral hypersensitivity and central maladaptive processing of visceral pain input. Stress and concomitant psychopathologies such as somatization, anxiety and depression are thought to play a major role in the development, clinical course and response to treatment. Psychopharmacological agents such as selective serotonin/serotonin-norepinephrine receptor antagonists, tricyclic antidepressants as well as other agents are commonly used in treating moderate to severe IBS. This review will provide the pathophysiological rationale for the use of psychopharmacological agents in IBS, review the main classes of drugs and evidence for their use in IBS and offer a practical approach to the use of these drugs. EXPERT OPINION: Psychotropic drugs can play a pivotal role in the treatment of IBS patients, so doctors should be familiar with their use. Further research with these drugs is needed to solidify our current knowledge and increase our therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316916     DOI: 10.1517/13543784.2013.761205

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  28 in total

1.  Perceived Stress, Its Physiological Correlates, and Quality of Life in Patients With Irritable Bowel Syndrome.

Authors:  Kristen R Weaver; Gail D'Eramo Melkus; Jason Fletcher; Wendy A Henderson
Journal:  Biol Res Nurs       Date:  2018-02-05       Impact factor: 2.522

Review 2.  Antidepressants in inflammatory bowel disease.

Authors:  Antonina Mikocka-Walus; Alexander C Ford; Douglas A Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-18       Impact factor: 46.802

3.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

4.  Advances in IBS 2016: A Review of Current and Emerging Data.

Authors:  Philip S Schoenfeld
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-08

Review 5.  Opioid misuse in gastroenterology and non-opioid management of abdominal pain.

Authors:  Eva Szigethy; Mitchell Knisely; Douglas Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-15       Impact factor: 46.802

6.  Neuroimaging the brain-gut axis in patients with irritable bowel syndrome.

Authors:  Kristen R Weaver; LeeAnne B Sherwin; Brian Walitt; Gail D'Eramo Melkus; Wendy A Henderson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

Review 7.  Impact of psychological stress on irritable bowel syndrome.

Authors:  Hong-Yan Qin; Chung-Wah Cheng; Xu-Dong Tang; Zhao-Xiang Bian
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

8.  SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-02

9.  Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.

Authors:  Ling Lan; Yu-Long Chen; Hao Zhang; Bai-Ling Jia; Yan-Jun Chu; Jin Wang; Shi-Xiao Tang; Guo-Dong Xia
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 10.  Managing irritable bowel syndrome.

Authors:  Joyce K Anastasi; Bernadette Capili; Michelle Chang
Journal:  Am J Nurs       Date:  2013-07       Impact factor: 2.220

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.